Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 7—July 2020

Case Manifestations and Public Health Response for Outbreak of Meningococcal W Disease, Central Australia, 2017

Eva L. SudburyComments to Author , Siobhan O’Sullivan, David Lister, Deepa Varghese, and Keshan Satharasinghe
Author affiliations: Alice Springs Hospital, Alice Springs, Northern Territory, Australia

Main Article

Table 1

Diagnostic categories of patients with meningococcal serogroup W infection, Central Australia, 2017*

Diagnostic category (reference) Clinical signs/symptoms Site of MenW isolation by culture or PCR Additional investigations
Meningococcemia (28,29) Fever (temperature >38°C) without a focus Blood None
Meningitis Fever; any signs of meningism (e.g., headache, neck stiffness, photophobia) CSF None
Bacteremic pneumonia (7,26,27) Fever; cough Blood Radiologic consolidation by chest radiograph
Septic arthritis (7) Fever; joint pain and swelling Synovial fluid None
Conjunctivitis (10,11) Conjunctival inflammation with purulent discharge Eye discharge None

*CSF, cerebrospinal fluid; MenW, serogroup W of Neisseria meningitidis.

Main Article

  1. Borrow  R, Alarcón  P, Carlos  J, Caugant  DA, Christensen  H, Debbag  R, et al.; Global Meningococcal Initiative. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16:31328. DOIPubMedGoogle Scholar
  2. Manchanda  V, Gupta  S, Bhalla  P. Meningococcal disease: history, epidemiology, pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and prevention. Indian J Med Microbiol. 2006;24:719. DOIPubMedGoogle Scholar
  3. Veitch  MG, Owen  RL. Rise in invasive serogroup W meningococcal disease in Australia 2013-2015. Commun Dis Intell Q Rep. 2016;40:E4513.PubMedGoogle Scholar
  4. Lewis  LA, Ram  S. Meningococcal disease and the complement system. Virulence. 2014;5:98126. DOIPubMedGoogle Scholar
  5. Thompson  MJ, Ninis  N, Perera  R, Mayon-White  R, Phillips  C, Bailey  L, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367:397403. DOIPubMedGoogle Scholar
  6. Martin  NV, Ong  KS, Howden  BP, Lahra  MM, Lambert  SB, Beard  FH, et al.; Communicable Diseases Network Australia MenW Working Group. Rise in invasive serogroup W meningococcal disease in Australia 2013-2015. Commun Dis Intell Q Rep. 2016;40:E4549.PubMedGoogle Scholar
  7. Vienne  P, Ducos-Galand  M, Guiyoule  A, Pires  R, Giorgini  D, Taha  M-K, et al. The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia. Clin Infect Dis. 2003;37:163942. DOIPubMedGoogle Scholar
  8. Campbell  H, Parikh  SR, Borrow  R, Kaczmarski  E, Ramsay  ME, Ladhani  SN. Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016. Euro Surveill. 2016;21:14. DOIPubMedGoogle Scholar
  9. Schaad  UB. Arthritis in disease due to Neisseria meningitidis. Rev Infect Dis. 1980;2:8808. DOIPubMedGoogle Scholar
  10. Barquet  N, Gasser  I, Domingo  P, Moraga  FA, Macaya  A, Elcuaz  R. Primary meningococcal conjunctivitis: report of 21 patients and review. Rev Infect Dis. 1990;12:83847. DOIPubMedGoogle Scholar
  11. Orden  B, Martínez  R, Millán  R, Belloso  M, Pérez  N. Primary meningococcal conjunctivitis. Clin Microbiol Infect. 2003;9:12457. DOIPubMedGoogle Scholar
  12. Lingappa  JR, Al-Rabeah  AM, Hajjeh  R, Mustafa  T, Fatani  A, Al-Bassam  T, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis. 2003;9:66571. DOIPubMedGoogle Scholar
  13. Yezli  S, Assiri  AM, Alhakeem  RF, Turkistani  AM, Alotaibi  B. Meningococcal disease during the Hajj and Umrah mass gatherings. Int J Infect Dis. 2016;47:604. DOIPubMedGoogle Scholar
  14. Ladhani  SN, Ramsay  M, Borrow  R, Riordan  A, Watson  JM, Pollard  AJ. Enter B and W: two new meningococcal vaccine programmes launched. Arch Dis Child. 2016;101:915. DOIPubMedGoogle Scholar
  15. Smith-Palmer  A, Oates  K, Webster  D, Taylor  S, Scott  KJ, Smith  G, et al. IMT and investigation team in Sweden. Outbreak of Neisseria meningitidis capsular group W among scouts returning from the World Scout Jamboree, Japan, 2015. Euro Surveill. 2016;21:17. DOIGoogle Scholar
  16. Nathan  N, Rose  AMC, Legros  D, Tiendrebeogo  SRM, Bachy  C, Bjørløw  E, et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis. 2007;13:9203. DOIPubMedGoogle Scholar
  17. von Gottberg  A, du Plessis  M, Cohen  C, Prentice  E, Schrag  S, de Gouveia  L, et al.; Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis. 2008;46:37786. DOIPubMedGoogle Scholar
  18. Abad  R, López  EL, Debbag  R, Vázquez  JA. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America. Epidemiol Infect. 2014;142:246170. DOIPubMedGoogle Scholar
  19. Campbell  H, Saliba  V, Borrow  R, Ramsay  M, Ladhani  SN. Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015. Euro Surveill. 2015;20:21188. DOIPubMedGoogle Scholar
  20. Australian Government Department of Health. Invasive meningococcal disease national surveillance report, December 2017 [cited 2018 Jun 27].$File/1Jan-31-Dec2017-Consol-Invasive-Men-W.pdf
  21. National Centre for Immunisation Research and Surveillance. History of vaccination in Australia, December 2017 [cited 2018 Jun 18].
  22. Dolan Thomas  J, Hatcher  CP, Satterfield  DA, Theodore  MJ, Bach  MC, Linscott  KB, et al. sodC-based real-time PCR for detection of Neisseria meningitidis. PLoS One. 2011;6:e19361. DOIPubMedGoogle Scholar
  23. Jordens  JZ, Heckels  JE. A novel porA-based real-time PCR for detection of meningococcal carriage. J Med Microbiol. 2005;54:4636. DOIPubMedGoogle Scholar
  24. Jolley  KA, Brehony  C, Maiden  MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev. 2007;31:8996. DOIPubMedGoogle Scholar
  25. Australian Bureau of Statistics. 2016 Census: Aboriginal and/or Torres Strait Islander peoples QuickStats [cited 2019 Aug 16].
  26. Vossen  M, Mitteregger  D, Steininger  C. Meningococcal pneumonia. Vaccine. 2016;34:436470. DOIPubMedGoogle Scholar
  27. Romero-Gomez  MP, Rentero  Z, Paño  JR, Mingorance  J. Bacteraemic pneumonia caused by Neisseria meningitidis serogroup Y. Respir Med Case Rep. 2012;5:234. DOIPubMedGoogle Scholar
  28. Centre for Disease Control. Meningococcal disease: signs and symptoms [cited 2019 Aug 22].
  29. Gaschignard  J, Levy  C, Deghmane  AE, Dubos  F, Muszlak  M, Cohen  R, et al. Invasive serogroup w meningococcal disease in children: a national survey from 2001 to 2008 in France. Pediatr Infect Dis J. 2013;32:798800. DOIPubMedGoogle Scholar
  30. Communicable Diseases Network Australia. Invasive meningococcal disease CDNA national guidelines for public health units, 2017 [cited 2019 Aug 22].$File/IMD-SoNG.pdf
  31. The Northern Territory Department of Health. Brief for the meningococcal outbreak task force. Darwin: The Department; 2018.
  32. Australian Government Department of Health. Meningococcal disease (invasive) public dataset. National Notifiable Diseases Surveillance System [cited 2019 Aug 13].
  33. PubMLST. Neisseria profile/sequence definitions database [cited 2019 Aug 15].
  34. Rosenstein  NE, Perkins  BA, Stephens  DS, Lefkowitz  L, Cartter  ML, Danila  R, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180:1894901. DOIPubMedGoogle Scholar
  35. Rosenstein  NE, Perkins  BA, Stephens  DS, Popovic  T, Hughes  JM. Meningococcal disease. N Engl J Med. 2001;344:137888. DOIPubMedGoogle Scholar
  36. Harley  D, Hanna  JN, Hills  SL, Bates  JR, Smith  HV. Epidemiology of invasive meningococcal disease in north Queensland, 1995 to 1999. Commun Dis Intell Q Rep. 2002;26:4450.PubMedGoogle Scholar
  37. Massey  P, Durrheim  D. Aboriginal and Torres Strait Islander peoples at higher risk of invasive meningococcal disease in NSW. N S W Public Health Bull. 2008;19:1003. DOIPubMedGoogle Scholar
  38. Australian Government. Australian Institute of Health and Welfare. Vaccine preventable disease among Aboriginal and Torres Strait Islander people [cited 2019 Aug 22].
  39. Cuningham  W, McVernon  J, Lydeamore  MJ, Andrews  RM, Carapetis  J, Kearns  T, et al. High burden of infectious disease and antibiotic use in early life in Australian Aboriginal communities. Aust N Z J Public Health. 2019;43:14955. DOIPubMedGoogle Scholar
  40. Hendrickx  D, Bowen  AC, Marsh  JA, Carapetis  JR, Walker  R. Ascertaining infectious disease burden through primary care clinic attendance among young Aboriginal children living in four remote communities in Western Australia. PLoS One. 2018;13:e0203684. DOIPubMedGoogle Scholar
  41. Parnaby  MG, Carapetis  JR. Rheumatic fever in indigenous Australian children. J Paediatr Child Health. 2010;46:52733. DOIPubMedGoogle Scholar
  42. Bilukha  OO, Rosenstein  N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):121.PubMedGoogle Scholar
  43. Umaru  ET, Ludin  AN, Majid  MR, Sabri  S, Moses  C, Enegbuma  W, et al. Risk factors responsible for the spread of meningococcal meningitis. Int J Educ Res. 2013;1:130.
  44. Olea  A, Matute  I, González  C, Delgado  I, Poffald  L, Pedroni  E, et al. Case–control study of risk factors for meningococcal disease in Chile. Emerg Infect Dis. 2017;23:10708. DOIPubMedGoogle Scholar
  45. Ladhani  SN, Beebeejaun  K, Lucidarme  J, Campbell  H, Gray  S, Kaczmarski  E, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60:57885. DOIPubMedGoogle Scholar
  46. Moreno  G, López  D, Vergara  N, Gallegos  D, Advis  MF, Loayza  S. [Clinical characterization of cases with meningococcal disease by W135 group in Chile, 2012] [in Spanish]. Rev Chilena Infectol. 2013;30:35060.PubMedGoogle Scholar
  47. Lahra  MM, Enriquez  R. Australian meningococcal surveillance programme annual report, 2016. Commun Dis Intell Q Rep. 2017;41:E36982.PubMedGoogle Scholar
  48. Mowlaboccus  S, Jolley  KA, Bray  JE, Pang  S, Lee  YT, Bew  JD, et al. Clonal expansion of new penicillin-resistant clade of Neisseria meningitidis serogroup W clonal complex 11, Australia. Emerg Infect Dis. 2017;23:13647. DOIPubMedGoogle Scholar
  49. Goedvolk  CA, von Rosenstiel  IA, Bos  AP. Immune complex associated complications in the subacute phase of meningococcal disease: incidence and literature review. Arch Dis Child. 2003;88:92730. DOIPubMedGoogle Scholar
  50. Sanofi-Aventis Pte Ltd. Menactra: meningococcal (groups A,C,Y and W-135) polysaccharide diptheria toxoid conjugate vaccine Australian product information, 2011 [cited 2020 Mar 31].

Main Article

Page created: March 31, 2020
Page updated: June 18, 2020
Page reviewed: June 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.